Purchase this article with an account.
Y. C. Yang, ANCHOR Study Group; Two Year Contrast Sensitivity Results From the Anchor Study Comparing Intravitreal Ranibizumab 0.3mg and 0.5mg With Verteporfin PDT for Predominantly Classic CNV Lesions Secondary to Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4545.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The ANCHOR study was designed to investigate the efficacy and safety of monthly intravitreal ranibizumab compared to verteporfin PDT in predominantly classic lesions secondary to AMD over two years.
In the ANCHOR trial, patients were randomized to receive monthly intravitreal ranibizumab 0.3mg plus sham PDT (n=140) or ranibizumab 0.5mg plus sham PDT (n=143), or verteporfin-PDT plus sham ranibizumab (n=140). Contrast sensitivity was assessed using Pelli-Robson charts, measuring the number of correctly identified letters.
At the Month-12 timepoint, monthly administration of both doses of ranibizumab increased contrast sensitivity over baseline by a mean of approximately 3 and 4 letters, respectively (both p<00001), in the ranibizumab 0.3mg and 0.5mg treatment groups. Contrast sensitivity in the verteporfin PDT group demonstrated a mean decrease of 3 letters at 12 months. Two year results from the ANCHOR study are currently under analysis and will be presented at this meeting.
Interim 12 month results from the ANCHOR study demonstrate that ranibizumab 0.3mg and 0.5mg significantly improved contrast sensitivity in predominantly classic CNV lesion types when assessed using Pelli-Robson charts. Two-year data from ANCHOR will be presented.
This PDF is available to Subscribers Only